Literature DB >> 12757980

Telomerase as tumor marker.

Eiso Hiyama1, Keiko Hiyama.   

Abstract

Telomerase, a critical enzyme responsible for continuous cell growth, is repressed in most somatic cells except proliferating progenitor cells and activated lymphocytes, and activated in approximately 85% of human cancer tissues. Telomerase activity is a useful cancer-cell detecting marker in some types of cancers in which almost all cases show telomerase activation. In other types in which telomerase becomes upregulated according to tumor progression, it is a useful prognostic indicator. Detection of human telomerase reverse transcriptase (hTERT) mRNA or protein in various clinical samples is also applicable. However, careful attention should be paid to the false negative results due to the instability of this enzyme or hTERT mRNA and the existence of polymerase chain reaction inhibitors as well as the false-positive results due to the contamination by normal cells with telomerase activity. If these pitfalls are avoided, in situ detection of hTERT mRNA or protein will facilitate the reliability of telomerase as a tumor marker.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12757980     DOI: 10.1016/s0304-3835(02)00709-7

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  45 in total

1.  Effects of tea polyphenols on proliferation and apoptosis of cadmium-transformed cells.

Authors:  Min Wang; Yi-Xiong Lei
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 2.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

Review 3.  Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.

Authors:  Camille Jacqueline; Olivera J Finn
Journal:  Semin Immunol       Date:  2020-04-06       Impact factor: 11.130

4.  Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.

Authors:  Xiaoming Xie; Yanan Kong; Hailin Tang; Lu Yang; Jennifer L Hsu; Mien-Chie Hung
Journal:  Mol Cancer Ther       Date:  2014-04-30       Impact factor: 6.261

5.  An unbiased in vivo screen reveals multiple transcription factors that control HPV E6-regulated hTERT in keratinocytes.

Authors:  Mei Xu; Rachel A Katzenellenbogen; Carla Grandori; Denise A Galloway
Journal:  Virology       Date:  2013-08-08       Impact factor: 3.616

Review 6.  Telomeres and telomerase in the clinical management of colorectal cancer.

Authors:  C Piñol-Felis; T Fernández-Marcelo; J Viñas-Salas; C Valls-Bautista
Journal:  Clin Transl Oncol       Date:  2016-10-19       Impact factor: 3.405

7.  Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.

Authors:  Jian Yan; Panyupa Pankhong; Thomas H Shin; Nyamekye Obeng-Adjei; Matthew P Morrow; Jewell N Walters; Amir S Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Cancer Immunol Res       Date:  2013-07-17       Impact factor: 11.151

8.  ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells.

Authors:  Sook Shin; Sangphil Oh; Seayoon An; Ralf Janknecht
Journal:  Oncol Rep       Date:  2012-10-16       Impact factor: 3.906

9.  Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Authors:  Caroline Laheurte; Jeanne Galaine; Laurent Beziaud; Magalie Dosset; Jerome Kerzerho; Claire Jacquemard; Béatrice Gaugler; Christophe Ferrand; Anne Dormoy; François Aubin; Pascale Jacoulet; Virginie Westeel; Christophe Borg; Eric Tartour; Yann Godet; Bernard Maillère; Olivier Adotévi
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

10.  Inhibition of human telomerase reverse transcriptase in vivo and in vitro for retroviral vector-based antisense oligonucleotide therapy in ovarian cancer.

Authors:  Z Qi; R Mi
Journal:  Cancer Gene Ther       Date:  2016-01-08       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.